BRAF V600E is found in ~4% of multiple myeloma at diagnosis (more in extramedullary / pla...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BRAF-V600E-MM |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-MM |
| Sources | SRC-CIVIC SRC-NCCN-MM-2025 |
Actionability Facts
| Biomarker | BIO-BRAF-V600E |
|---|---|
| Variant | V600E |
| Disease | DIS-MM |
| ESCAT tier | IIIA |
| Recommended combinations | dabrafenib + trametinib (off-label, R/R plasmablastic / extramedullary), vemurafenib (case-report level) |
| Evidence summary | BRAF V600E is found in ~4% of multiple myeloma at diagnosis (more in extramedullary / plasma cell leukemia). Case series and small prospective cohorts (Andrulis et al. 2013, Sharman et al. 2015) document responses to vemurafenib monotherapy and BRAFi+MEKi combinations off-label, especially in plasmablastic / aggressive R/R disease. Not standard-of-care; tissue-agnostic dabrafenib + trametinib (BRAF V600E solid tumor approval 2022) does not formally extend to heme but is invoked as off-label rationale. |
Notes
ESCAT IIIA — clinical benefit in other tumor types (case reports + small series in MM). OncoKB Level 3B. Not in NCCN MM standard algorithms; consider only after standard novel-agent regimens exhausted, ideally in clinical trial / MyDRUG basket.
Used By
No reverse references found in the YAML corpus.